Dr. Filippo Milano and colleagues in the Cord Blood Program at Fred Hutch have received funding from the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation to support a clinical trial to improve the use of umbilical cord blood as a treatment for leukemia ... and more good news at Fred Hutch.
New research writes latest chapter in one drug's story
June 27, 2017
| by Susan Keown / Fred Hutch News Service
The leukemia drug gemtuzumab ozogamicin (Mylotarg) was pulled from the market seven years after initial approval. Now, new evidence may be bringing it back to life to treat a specific group of patients.
30 years after an early BMT, a cancer survivor pays it forward by helping researchers ‘make it better for others’
March 29, 2017
| By Diane Mapes / Fred Hutch News Service
The road to a cure was not easy for Mike Rubin, who underwent a bone marrow transplant in 1987. But 30 years after the lifesaving procedure, this survivor and Fred Hutch fundraiser is celebrating -- and paying it forward so others can do the same.
New technology allows scientists to peek inside nearly 70,000 cells in single experiment
Jan. 16, 2017
| By Sabrina Richards / Fred Hutch News Service
Researchers have developed a new technique which allows them to examine huge amounts of information from a single cell or zoom out and see data patterns among thousands upon thousands of cells — all in a single experiment. The method could help researchers dive deep into the ecosystem of cancer.
Four things to watch from the 2016 annual meeting of the American Society of Hematology
Dec. 20, 2016
| By Susan Keown / Fred Hutch News Service
For a few days earlier this month, a small city’s-worth of health professionals and researchers from nations across the globe converged for the world’s biggest conference in hematology. Fred Hutch News Service was on the ground at the annual meeting of the American Society of Hematology Dec. 3-6 in San Diego, California.
From immunotherapy for advanced blood cancers to new approaches to treating sickle cell disease, here’s our top four things to watch from the meeting.